Fig. 8.

TEAD1 promoted EMT by transcriptional up-regulation TWIST1. a. TCGA cohort analysis of the Twist1 expression in ccRCC tumor samples and pair-matched normal tissues. b-c. Kaplan–Meier analysis indicated that higher level of Twist1 expression was associated with worse overall survival(b) and disease-free survival(c). d. TEAD1 response element motif sequences. e. Bioinformatics analysis of potential TEAD1-binding sites in 1 kb of Twist1 promoter region using Jaspar database. f. ChIP assays showing that TEAD1 can bind to potential binding sites in the Twist1 promoter. g. Diagram of TEAD1E I-mut and TEAD1E V- mut in the Twist1 promoter. h-i. Co-transfection of TEAD1E wildtype or mutant in Twist1 promoter pGL3-Luciferase constructs, then into A498 cells with/without TEAD1(h), and into 786-O cells with/without Peptide 17(i). The luciferase assay was applied to detect the promoter activity. **P<0.01, NS-not significant compared to the controls. The n values indicate the number of patients. Data are given as mean ± SD, N.S, not significant, *P < 0.05, **P < 0.01(Student's t-test).